BNP Paribas Financial Markets’s AgomAb Therapeutics NV AGMB Stock Holding History

BNP Paribas Financial Markets’s Portfolio AGMB Stock Details AGMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.79K	Buy	+754	New	+$8.49K	﹤0.01%	5382

Other funds holding AGMB

EFM

EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Andera Partners Paris $206M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BNP Paribas Financial Markets's AGMB Position: Q2 2026 in Review

BNP Paribas Financial Markets opened a new position in AgomAb Therapeutics NV (AGMB) in Q2 2026: 754 shares worth $9.79K. The stake represents ﹤0.01% of the portfolio and ranks #5382 among its holdings.

34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

BNP Paribas Financial Markets held 754 shares of AgomAb Therapeutics NV worth $9.79K as of Q2 2026.
AgomAb Therapeutics NV was a new BNP Paribas Financial Markets position in Q2 2026.
AgomAb Therapeutics NV made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5382 holding.
34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.